Korro Bio (KRRO) AI Stock Analysis

• Market Cap: $75.34M
• Dividend Yield: N/A
• Average Volume (3M): 734.66K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.47
• Revenue Growth: N/A
• EPS Growth: 21.61%
• Country: US
• Employees: 112
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.92
• Shares Outstanding: 9,417,295
• 10 Day Avg. Volume: 1,808,258
• 30 Day Avg. Volume: 734,659
• PEG Ratio: 0.05
• Price to Book (P/B): 2.12
• Price to Sales (P/S): 149.54
• P/FCF Ratio: -4.36
• Enterprise Value/Market Cap: 5.32
• Enterprise Value/Revenue: 54.40
• Enterprise Value/Gross Profit: 54.40
• Enterprise Value/Ebitda: -4.53
• 1Y Price Target: $25.75
• Price Target Upside: 211.74% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 8
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 44 Neutral
• Price Target: $8.00 ▼(-3.15% Downside)

The score is pressured primarily by weak financial performance driven by large losses and significant cash burn, plus bearish technicals with the stock far below key moving averages and a negative MACD. Valuation provides limited support due to negative earnings and no dividend yield, while recent corporate actions are mixed, with restructuring and a paused major collaboration weighing on sentiment.

Positive Factors

Strong Cash Reserves

Strong cash reserves provide Korro Bio with the financial flexibility to continue investing in R&D and support its growth strategy without immediate liquidity concerns.

Positive Revenue Turnaround

The shift from zero to some revenue indicates initial market traction for Korro Bio's products, suggesting potential for future revenue growth as their RNA editing therapies gain acceptance.

Leadership Stability

The return of the CFO ensures continuity in financial leadership, which is crucial for strategic planning and maintaining investor confidence during critical growth phases.

Negative Factors

High R&D Costs

High R&D costs can strain financial resources, impacting profitability and necessitating ongoing external funding, which may dilute existing shareholders over time.

Negative Cash Flow

Negative cash flows highlight operational inefficiencies and reliance on external financing, which could limit Korro Bio's ability to sustain long-term growth without additional capital.

Substantial Losses

Ongoing substantial losses indicate that Korro Bio's current revenue is insufficient to cover its operational costs, posing a risk to financial sustainability if not addressed.

Korro Bio Business Overview & Revenue Model

Company Description

Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts.

How the Company Makes Money

Korro Bio Financial Statement Overview

Summary

Korro Bio's financials reflect a typical biotech profile with high R&D costs and reliance on external financing. The income statement shows a recent move from zero revenue to some revenue, but with substantial losses. The balance sheet is mixed, with strong cash reserves but past equity concerns. Cash flow is negative, highlighting operational struggles.

Income Statement

Korro Bio has seen significant challenges in generating revenue, with a recent turnaround from zero revenue to a small amount. However, the company continues to face substantial losses with a negative net profit margin. The gross profit margin is positive, but EBIT and EBITDA margins are deeply negative, indicating high operational costs that outweigh revenue.

Balance Sheet

The balance sheet presents a mixed picture. On one hand, the company has a strong equity position and cash reserves, with a low debt-to-equity ratio suggesting limited leverage. However, the negative stockholders' equity in earlier years poses a concern about financial stability, though recent improvements are visible.

Cash Flow

Cash flow analysis indicates that the company is struggling with negative operating and free cash flows, which is common for biotech firms focusing on R&D. There is, however, a significant inflow from financing activities, suggesting reliance on external funding to support operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	7.37M	2.27M	0.00	0.00	14.07M	36.98M
Gross Profit	7.37M	2.27M	0.00	0.00	10.23M	35.40M
EBITDA	-88.44M	-88.34M	-80.90M	-56.49M	-80.07M	-24.90M
Net Income	-88.42M	-83.58M	-81.17M	-58.03M	-84.69M	-26.51M
Balance Sheet
Total Assets	161.55M	226.24M	221.66M	73.74M	185.36M	264.72M
Cash, Cash Equivalents and Short-Term Investments	93.48M	126.09M	166.15M	55.85M	130.71M	220.34M
Total Debt	44.67M	44.77M	33.21M	166.99M	45.60M	45.99M
Total Liabilities	62.52M	65.83M	51.75M	172.77M	54.53M	72.23M
Stockholders Equity	99.03M	160.41M	169.91M	-99.03M	130.82M	192.49M
Cash Flow
Free Cash Flow	-70.24M	-77.98M	-75.12M	-58.86M	-36.54M	-51.86M
Operating Cash Flow	-68.35M	-60.07M	-67.28M	-53.65M	-32.09M	-45.19M
Investing Cash Flow	26.31M	-123.35M	11.16M	11.06M	-39.50M	10.40M
Financing Cash Flow	1.24M	69.36M	187.76M	18.00K	115.94M	56.69M

Korro Bio Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 8.26
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KRRO, the sentiment is Neutral. The current price of 8.26 is above the 20-day moving average (MA) of 8.00, below the 50-day MA of 15.14, and below the 200-day MA of 19.86, indicating a neutral trend. The MACD of -1.48 indicates Negative momentum. The RSI at 37.66 is Neutral, neither overbought nor oversold. The STOCH value of 43.41 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for KRRO.

Korro Bio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ANNX	57 Neutral	$755.49M	-3.62	-83.98%	―	―	-35.62%
DSGN	55 Neutral	$495.02M	-7.43	-29.83%	―	―	-40.26%
ASMB	53 Neutral	$511.05M	-6.37	-36.94%	―	31.30%	32.79%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
FDMT	47 Neutral	$417.09M	-1.83	-45.38%	―	―	―
KRRO	44 Neutral	$75.34M	-0.88	-63.46%	―	―	21.61%
AURA	42 Neutral	$328.95M	-2.68	-64.26%	―	―	-11.41%

Korro Bio Corporate Events

Korro Bio Enhances Executive Compensation and Retention Incentives

On December 15, 2025, Korro Bio, Inc. amended and restated the employment agreement of executive Jeffrey Cerio, keeping most terms consistent with his August 28, 2024 contract but raising his annual base salary to $425,000 and enhancing his severance protections, including longer payout periods in the event of termination without cause or resignation for good reason, particularly following a change in control. As part of a broader employee appreciation and retention effort, Korro also granted Cerio a $100,000 cash bonus, payable in two tranches in late 2025 and mid-2026 contingent on continued service, and awarded him 41,902 restricted stock units vesting in mid-2026 and late 2026, underscoring the company’s focus on retaining key leadership through more robust cash and equity incentives.

The most recent analyst rating on (KRRO) stock is a Hold with a $81.00 price target. To see the full list of analyst forecasts on Korro Bio stock, see the KRRO Stock Forecast page.

Korro Bio Pauses Novo Nordisk Collaboration Amid Restructuring

On November 11, 2025, Korro Bio and Novo Nordisk agreed to pause their research collaboration and license agreement for 12 months, allowing Korro to wind down its activities during this period with Novo Nordisk reimbursing certain costs. This strategic move is part of Korro’s broader restructuring efforts, which include a 34% workforce reduction to extend its cash runway into the second half of 2027. Additionally, Korro announced the resignation of its Chief Medical Officer, Dr. Olukemi A. Olugemo, effective November 12, 2025, who will continue as an advisor for three months post-resignation. These changes are aimed at refocusing resources on advancing Korro’s RNA editing platform and GalNAc-conjugated programs targeting liver diseases.

The most recent analyst rating on (KRRO) stock is a Buy with a $93.00 price target. To see the full list of analyst forecasts on Korro Bio stock, see the KRRO Stock Forecast page.

Korro Bio CFO Vineet Agarwal Resigns, Interim Appointed

On October 7, 2025, Vineet Agarwal announced his resignation as Chief Financial Officer of Korro Bio, effective October 17, 2025, to pursue another opportunity. He will serve as an advisor for 30 days post-resignation to ensure a smooth transition. His departure is amicable and not due to any disagreements with the company. Korro Bio’s board has appointed Dr. Ram Aiyar, the current President and CEO, as interim CFO effective October 17, 2025, without additional compensation. This transition is aimed at maintaining stability within the company’s financial operations.

The most recent analyst rating on (KRRO) stock is a Buy with a $180.00 price target. To see the full list of analyst forecasts on Korro Bio stock, see the KRRO Stock Forecast page.